PYXS vs. RANI, ADCT, MGNX, STTK, ACET, CNTA, ARCT, SPRY, ARQT, and PRTC
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Rani Therapeutics (RANI), ADC Therapeutics (ADCT), MacroGenics (MGNX), Shattuck Labs (STTK), Adicet Bio (ACET), Centessa Pharmaceuticals (CNTA), Arcturus Therapeutics (ARCT), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical preparations" industry.
Rani Therapeutics (NASDAQ:RANI) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
Rani Therapeutics' return on equity of -38.99% beat Pyxis Oncology's return on equity.
In the previous week, Rani Therapeutics had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for Rani Therapeutics and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.51 beat Rani Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Rani Therapeutics currently has a consensus target price of $12.20, suggesting a potential upside of 177.90%. Pyxis Oncology has a consensus target price of $8.80, suggesting a potential upside of 131.58%. Given Pyxis Oncology's higher probable upside, equities analysts plainly believe Rani Therapeutics is more favorable than Pyxis Oncology.
Rani Therapeutics received 3 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 76.67% of users gave Rani Therapeutics an outperform vote.
Rani Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Rani Therapeutics has higher revenue and earnings than Pyxis Oncology. Rani Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Rani Therapeutics beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
